Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Dr Erica Mayer, including the following topics:
- Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
- Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
- Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)
- Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)
- Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)
- Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)
- Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)
- Investigator Survey Results on Adjuvant Oral SERDs (43:02)
- Discussion of Questions from the Community (45:00)
CME information and select publications
